SRCP1 Conveys Resistance to Polyglutamine Aggregation. Mol Cell 2018 Jul 19;71(2):216-228.e7
Date
07/22/2018Pubmed ID
30029002Pubmed Central ID
PMC6091221DOI
10.1016/j.molcel.2018.07.008Scopus ID
2-s2.0-85049861465 (requires institutional sign-in at Scopus site) 13 CitationsAbstract
The polyglutamine (polyQ) diseases are a group of nine neurodegenerative diseases caused by the expansion of a polyQ tract that results in protein aggregation. Unlike other model organisms, Dictyostelium discoideum is a proteostatic outlier, naturally encoding long polyQ tracts yet resistant to polyQ aggregation. Here we identify serine-rich chaperone protein 1 (SRCP1) as a molecular chaperone that is necessary and sufficient to suppress polyQ aggregation. SRCP1 inhibits aggregation of polyQ-expanded proteins, allowing for their degradation via the proteasome, where SRCP1 is also degraded. SRCP1's C-terminal domain is essential for its activity in cells, and peptides that mimic this domain suppress polyQ aggregation in vitro. Together our results identify a novel type of molecular chaperone and reveal how nature has dealt with the problem of polyQ aggregation.
Author List
Santarriaga S, Haver HN, Kanack AJ, Fikejs AS, Sison SL, Egner JM, Bostrom JR, Seminary ER, Hill RB, Link BA, Ebert AD, Scaglione KMAuthors
Allison D. Ebert PhD Center Director, Professor in the Neuroscience Research Center department at Medical College of WisconsinBrian A. Link PhD Professor in the Cell Biology, Neurobiology and Anatomy department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Cell LineDictyostelium
HEK293 Cells
Humans
Molecular Chaperones
Peptides
Proteasome Endopeptidase Complex
Protein Binding
Serine
Ubiquitin